

1 Using the relationship between brain tissue regional saturation of oxygen and mean  
2 arterial pressure to determine the optimal mean arterial pressure in patients  
3 following cardiac arrest: A pilot proof-of-concept study  
4

5 Mypinder S Sekhon MD<sup>1</sup>, Peter Smielewski PhD<sup>2</sup>, Tahara D Bhate MD MHSc<sup>1</sup>,  
6 Penelope M Brasher PhD<sup>3</sup>, Denise Foster RN<sup>1</sup>, David K Menon MD PhD<sup>2</sup>,  
7 Arun K Gupta MD PhD<sup>2</sup>, Marek Czosnyka PhD<sup>4</sup>, William R Henderson MD<sup>1</sup>,  
8 Kenneth Gin MD<sup>5</sup>, Graham Wong MD MPH<sup>5</sup> and Donald E. Griesdale MD MPH<sup>1,3,6</sup>  
9

10 <sup>1</sup>Division of Critical Care Medicine, Department of Medicine, Vancouver General Hospital,  
11 University of British Columbia, Vancouver BC, Canada

12 <sup>2</sup>Neurocritical Care Unit, Addenbrooke's Hospital, Cambridge University Hospitals Trust,  
13 Cambridge University, Cambridge United Kingdom

14 <sup>3</sup>Centre for Clinical Epidemiology and Evaluation, Vancouver Coastal Health Research Institute,  
15 Vancouver BC, Canada

16 <sup>4</sup>Brain Physics Lab, Division of Neurosurgery, Cambridge University Hospitals Trust,  
17 Cambridge University, Cambridge, United Kingdom

18 <sup>5</sup>Division of Cardiology, Department of Medicine, Vancouver General Hospital, University of  
19 British Columbia, Vancouver BC, Canada

20 <sup>6</sup>Department of Anesthesia, Pharmacology and Therapeutics and Department of Medicine,  
21 Division of Critical Care Medicine, Vancouver General Hospital, University of British  
22 Columbia, Vancouver BC, Canada  
23

24 Corresponding Author:  
25 Dr. Donald Griesdale  
26 Critical Care Medicine  
27 Vancouver General Hospital  
28 Room 2438, Jim Pattison Pavilion, 2<sup>nd</sup> Floor  
29 855 West 12<sup>th</sup> Avenue  
30 Vancouver BC V5Z 1M9  
31 Phone: 604-875-5949  
32 Fax: 604-875-5957  
33 Email: [donald.griesdale@vch.ca](mailto:donald.griesdale@vch.ca)  
34

35 **Funding:** Dr. Griesdale is funded by the VGH & UBC Hospital Foundation Best of Health Fund.  
36 Medtronic PLC provided the INVOS® monitor and sensors free of charge. Medtronic had no  
37 involvement in study concept, design, conduct, analysis or interpretation.  
38

39 **Keywords:** cardiac arrest, cerebral autoregulation, cerebral oximetry

1 **Abstract**

2 Introduction: Prospectively assess cerebral autoregulation and optimal mean arterial pressure  
3 (MAP<sub>OPT</sub>) using the dynamic relationship between MAP and regional saturation of oxygen  
4 (rSO<sub>2</sub>) using near-infrared spectroscopy.

5 Methods: Feasibility study of twenty patients admitted to the intensive care unit following a  
6 cardiac arrest. All patients underwent continuous rSO<sub>2</sub> monitoring using the INVOS® cerebral  
7 oximeter. ICM+® brain monitoring software calculates the cerebral oximetry index (COx) in  
8 real-time which is a moving Pearson correlation coefficient between 30 consecutive, 10-sec  
9 averaged values of MAP and correspond rSO<sub>2</sub> signals. When rSO<sub>2</sub> increases with increasing  
10 MAP (COx ≥0.3), cerebral autoregulation is dysfunctional. Conversely, when rSO<sub>2</sub> remains  
11 constant or decreases with increasing MAP (COx <0.3), autoregulation is preserved. ICM+®  
12 fits a U-shaped curve through the COx values plotted versus MAP. The MAP<sub>OPT</sub> is nadir of this  
13 curve.

14 Results: The median age was 59 years (IQR 54 - 67) and 7 of 20 were female. The cardiac arrest  
15 was caused by myocardial infarction in 12 (60%) patients. Nineteen arrests were witnessed and  
16 return of spontaneous circulation occurred in a median of 15.5 minutes (IQR 8 – 33). Patients  
17 underwent a median of 30 hours (IQR 23 – 46) of monitoring. COx curves and MAP<sub>OPT</sub> were  
18 generated in all patients. The mean overall MAP and MAP<sub>OPT</sub> were 76 mmHg (SD 10) and 76  
19 mmHg (SD 7), respectively. MAP was outside of 5 mmHg from MAP<sub>OPT</sub> in 50% (SD 15) of the  
20 time. Out of the 7672 5-minute averaged COx measurements, 1182 (15%) were at 0.3 or above,  
21 indicating absence of autoregulation. Multivariable polynomial fractional regression  
22 demonstrated an increase in COx with increasing temperature (P=0.008).

23 Conclusions: We demonstrated the feasibility to determine a MAP<sub>OPT</sub> using cerebral oximetry in  
24 patients after cardiac arrest.

25  
26  
27  
28

# 1 Introduction

2 Hypoxemic-ischemic brain injury (HIBI) is the major cause of death in patients  
3 following cardiac arrest<sup>1</sup>. Furthermore, approximately half of those who survive will be left with  
4 an unfavourable neurologic outcome<sup>2</sup>. HIBI is characterized by cerebral edema with elevated  
5 intracranial pressure (ICP) and dysfunctional cerebral autoregulation<sup>3</sup>. In healthy individuals,  
6 cerebral autoregulation attempts to maintain constant cerebral blood flow (CBF) over a wide  
7 range of mean arterial pressure (MAP). In HIBI, autoregulation is impaired, with the plateau  
8 becoming narrowed and right-shifted<sup>4</sup>. This may have consequences for targeting a specific  
9 MAP threshold in these patients. If the MAP is below the autoregulatory threshold, additional  
10 ischemia can result, leading to further brain injury. Conversely, if the MAP above the  
11 autoregulatory threshold, excessive perfusion may lead to increased cerebral edema and  
12 worsening brain injury.

13 The American Heart Association recommends keeping MAP at 65mmHg or above in all  
14 patients following cardiac arrest<sup>5</sup>. However this “one size fits all” philosophy clearly does not  
15 take into consideration intra-subject variability and, moreover, any possible disruption in a  
16 patient’s cerebral autoregulation capacity. Recently, there has been interest in using the dynamic  
17 fluctuations in MAP on brain regional saturation of oxygen (rSO<sub>2</sub>) using near-infrared  
18 spectroscopy (NIRS)<sup>6,7</sup>. If MAP and rSO<sub>2</sub> trend in the same direction (e.g. decreasing MAP  
19 leads to equal reductions in rSO<sub>2</sub>), then effective cerebral autoregulation is likely severely  
20 compromised. Conversely, if rSO<sub>2</sub> remains constant during changes in MAP then autoregulation  
21 is likely intact. Over time, a moving correlation coefficient (a value between -1 and +1) between  
22 MAP and rSO<sub>2</sub> can be repeatedly calculated. This is termed the cerebral oximetry index (COx).  
23 A positive or negative COx indicates dysfunction or intact cerebral autoregulation, respectively<sup>8</sup>.  
24 The MAP<sub>OPT</sub> can then be identified at the point with the lowest COx<sup>7</sup>. This approach has been  
25 applied to two studies in patients after cardiac arrest using differing definitions of intact  
26 autoregulation<sup>6,9</sup>. We thus conducted a single center proof-of-concept study to determine if we  
27 could prospectively determine MAP<sub>OPT</sub> in a cohort of patients admitted after cardiac arrest. In  
28 addition, we wanted to determine additional feasibility outcomes: patient recruitment rates,  
29 duration of monitoring and adequacy of data capture. We also sought to assess the percentage of  
30 time of intact autoregulation and the ability to determine MAP<sub>OPT</sub>.

31

1 **Methods**

2 This is a single-center feasibility proof-of-concept study. The Research Ethics Board at  
3 the University of British Columbia (H14-02405) approved the protocol and written informed  
4 consent was obtained from patients in a deferred manner.

5 **Patient Inclusion**

6 We included patients 16 years or older who were admitted following a cardiac arrest who  
7 had a post-resuscitation Glasgow Coma Score of 8 or less. Patients had to be enrolled within 36  
8 hours of their cardiac arrest and had more than 20 consecutive minutes of spontaneous  
9 circulation following resuscitation. We excluded patients with a past history of cardiac arrest,  
10 traumatic brain injury, intracerebral hemorrhage or ischemic stroke. We also excluded patients  
11 where there was no commitment to ongoing support by the medical team.

12 **Patient Management**

13 All patient care decisions were at the discretion of the treating team. As per institutional  
14 protocol, patients who have a cardiac arrest from a presumed cardiac cause undergo targeted  
15 temperature management to either 33°C or 36°C, at the discretion of the attending physician.  
16 This is undertaken with surface cooling using the Artic Sun® Temperature Management System  
17 (Bard Medical, Murray Hill, NJ, USA). During the time of the study, there was no institutional  
18 temperature management protocol for cardiac arrest from a presumed non-cardiac cause (e.g.  
19 hypoxemia).

20  
21 **Study site**

22 Affiliated with the University of British Columbia, the intensive care unit (31 beds) and  
23 coronary care unit (14 beds) manage all of the post cardiac arrest patients at Vancouver General  
24 Hospital. The ICU and CCU are staffed by fellowship trained intensive care physicians and  
25 cardiologists, respectively.

26 **Neurophysiologic Monitoring**

27 We monitored brain regional saturation of oxygen (rSO2) bilaterally using the INVOS®  
28 cerebral oximeter (Covidien, Ireland) on the day of admission and continued for up to 48 hours

1 after the cardiac arrest. Invasive blood pressure and rSO<sub>2</sub> data were captured in real-time using  
2 ICM+® brain monitoring software (Division of Neurosurgery, Cambridge University). Daily  
3 during the study, two investigators (DG, MS) measured MCA flow velocity using TCD.  
4

## 5 **Statistical methods**

6         Categorical data are summarized as count (percent) and continuous data are summarized  
7 as mean (standard deviation) or median and interquartile range (25th - 75th percentile) if the data  
8 were skewed. We used Stata 10.0 (StataCorp, Texas, USA) for all analyses. All tests were two-  
9 sided and a p-value <0.05 was considered statistically significant. As this was a proof-of-  
10 concept study, no formal sample size calculation was performed. Twenty patients represented  
11 the maximum number of patients we could recruit with the available resources. TCD was used  
12 to estimate CPP using the following formula:  $CPP = MAP \times FVd/FVm + 14$ <sup>10</sup>. A non-invasive  
13 ICP was then estimated as  $ICP = MAP - CPP$ .

### 14 *Determination of CO<sub>x</sub> and MAP<sub>OPT</sub>.*

15         ICM+® brain monitoring software calculates both CO<sub>x</sub> and MAP<sub>OPT</sub>. CO<sub>x</sub> is a moving  
16 Pearson correlation coefficient between 30 consecutive, 10-sec averaged values of MAP and  
17 corresponding rSO<sub>2</sub> signals (with 80% overlap of data)<sup>11</sup>. For the purposes of analysis, we  
18 averaged the rSO<sub>2</sub>, MAP and CO<sub>x</sub> over a 5-minute time period<sup>8</sup>. To calculate MAP<sub>OPT</sub>, ICM+®  
19 divides MAP into bins of 5mmHg and then discards the first and last MAP bins. MAP bins  
20 which contain <2% of data points are also discarded<sup>12</sup>. ICM+® then fits a U-shaped curve  
21 through the CO<sub>x</sub> values plotted versus MAP<sup>13</sup>. The MAP<sub>OPT</sub> is the nadir of this curve. MAP<sub>OPT</sub>  
22 was calculated for each 6 hour time period. Figure 1 demonstrates data capture (MAP, rSO<sub>2</sub> and  
23 CO<sub>x</sub>) and the generation of MAP<sub>OPT</sub> in an individual patient. We then calculated the difference  
24 between the patients' actual average MAP (on an hourly basis) and the MAP<sub>OPT</sub>. Presence of  
25 cerebral autoregulation was defined *a priori* as a CO<sub>x</sub> <0.3<sup>8,14</sup>.

### 26 *Modeling of CO<sub>x</sub> with MAP and temperature*

27         The relationship was assessed visually by plotting CO<sub>x</sub> vs. MAP and CO<sub>x</sub> vs.  
28 temperature for each individual. For the relationship between CO<sub>x</sub> and MAP, the median and  
29 IQR for CO<sub>x</sub> was calculated for each 5mmHg bin of MAP of each individual. For the  
30 relationship between CO<sub>x</sub> and temperature, we overlaid the scatterplot with a locally weighted

1 scatterplot smoothing function conditioned on the individual. In order to visually assess the  
2 relationship between COx and temperature across all patients, we used restricted cubic splines.  
3 This relationship was modeled using fractional polynomials.

4

# 1 Results

2           Between December 1<sup>st</sup>, 2014 and March 27<sup>th</sup>, 2015, 22 patients were screened and 20  
3 enrolled. One patient refused and one patient could not be enrolled because the equipment was  
4 being used on another study patient. Recruitment rate was 5 patients per month. Overall, the  
5 median age was 59 years (IQR 54 – 67) and 6 of 20 (30%) were female. The majority of cardiac  
6 arrests were caused by myocardial infarctions (12 of 20, 60%) with 10 of 12 of these patients  
7 undergoing percutaneous coronary intervention. The arrest was witnessed in 19 of 20 (95%) of  
8 patients and ROSC occurred within a median of 15.5 minutes (8 – 33). The baseline  
9 characteristics are presented in table 1. The median time from ROSC until application of  
10 cerebral oximetry monitoring was 16.5 hours (9 – 19). Patients underwent a median of 30 hours  
11 (23 – 46) of monitoring, with one patient undergoing a total of 72 hours. The mean ONSD was  
12 5.9mm (0.5) and three patients had an estimated ICP of greater than 20 mmHg using TCD. All  
13 three of these patients died. Overall, 11 of 20 patients (55%) died in hospital. ICU management  
14 characteristics are presented in table 2. During the first 24 hours, 13 of 20 (60%) of patients  
15 underwent targeted temperature management with a goal temperature of 33°C (3 patients) or  
16 36°C (10 patients). For the twelve patients with a presumed cardiac cause of the cardiac arrest,  
17 the mean temperature for the first and second 24 hours were 35.4°C (1.4) and 36.1°C (1.7),  
18 respectively. For the 8 patients with a non-cardiac cause arrest, the mean temperature for the  
19 first and second 24 hours were 36.8°C (2.3) and 37.5°C (1.1), respectively. –

## 20 *Relationship between COx and MAP*

21           Examples of the relationship between COx and MAP for four individual patients over a  
22 6-hour period are presented in figure 2. There were several patterns that emerged. The U-  
23 shaped relationship (figure 2A) identified a zone of autoregulation. Some patients maintained  
24 autoregulation throughout the range of observable MAP (figure 2B). Other patterns included up-  
25 sloping (figure 2C) and down-sloping (figure 2D) relationships which might indicate  
26 dysfunctional autoregulation with increasing and decreasing MAP, respectively, or may simply  
27 represent a portion of a U-shaped relationship.

28           We were able to generate COx curves (e.g. figure 1) for at least one six-hour period in all  
29 twenty patients, including two patients who underwent veno-arterial extracorporeal life support.  
30 A MAP<sub>OPT</sub> was generated for all 6 hour time periods in 10 patients. In six patients, there was 1

1 missing period and in 3 patients there were two missing periods. In one patient, 5 of 13 periods  
2 were missing. The mean overall MAP and MAP<sub>OPT</sub> were 76 mmHg (10) and 76 mmHg (7),  
3 respectively. The mean percentage of time where the MAP was outside of 5 mmHg from  
4 MAP<sub>OPT</sub> was 50% (15). The MAP was greater than 5 mmHg above MAP<sub>OPT</sub> a mean of 22% (12)  
5 and greater than 5 mmHg below MAP<sub>OPT</sub> a mean of 28% (15). The density distribution of the  
6 difference between actual MAP and MAP<sub>OPT</sub> is presented in figure 3. The mean rSO<sub>2</sub> was 61%  
7 (11) and mean CO<sub>x</sub> was 0.066 (0.11). Out of the 7672 5-minute averaged CO<sub>x</sub> measurements,  
8 1182 (15%) were at 0.3 or above. On a per patient basis, this represents a median of 13% (6 –  
9 19) of time when the prevailing MAP was outside the autoregulatory range. The median  
10 percentage of time with a CO<sub>x</sub> of 0.3 or above was 18% (7 - 41) in those patients who died  
11 compared to 10% (6 - 13) for those who survived

#### 12 *Relationship between CO<sub>x</sub> and temperature*

13 Hourly temperature data was recorded in all 20 patients and the relationship between 5-  
14 minute CO<sub>x</sub> and hourly temperature is displayed in figure 4. Multivariable fractional polynomial  
15 regression demonstrated an increase in CO<sub>x</sub> with increasing temperature (P=0.008).

16

17

18

19

20

21

22



## 1 Discussion

2 In this single-centre proof-of-concept feasibility study we demonstrated the feasibility to  
3 use the dynamic relationship between MAP and rSO<sub>2</sub> to assess cerebral autoregulation in real-  
4 time. We were able to calculate a MAP<sub>OPT</sub> in all twenty patients and this was outside of 5  
5 mmHg from the actual MAP for half of the monitoring time. Furthermore, using a cutoff of CO<sub>x</sub>  
6 less than 0.3, autoregulation was present for the majority of time analyzed. Hyperthermia was  
7 associated with an increased CO<sub>x</sub> and autoregulation was preserved with hypothermia.

8 There has been increasing interest in determining the optimal blood pressure targets  
9 following cardiac arrest. Although multiple observational studies demonstrating improved  
10 neurologic outcomes associated with higher MAP<sup>15-19</sup>, these results are not consistent<sup>20</sup>.  
11 Furthermore, there is marked heterogeneity in these studies in terms of: patients included,  
12 definition of hypotension, and statistical modelling of blood pressure<sup>21</sup>. Given the lack of high-  
13 quality data<sup>22</sup>, the American Heart Association recommends keeping MAP at 65mmHg or  
14 greater in all patients following cardiac arrest<sup>5</sup>. However, it may be that given the right-shifted  
15 and narrowed zone of autoregulation observed after cardiac arrest<sup>3,23</sup>, we should be examining  
16 patient-specific blood pressure targets, rather than applying universal thresholds<sup>24</sup>.

17 Patient-specific blood pressure thresholds have been used in patients with traumatic brain  
18 injury (TBI)<sup>12</sup>, which shares similar pathophysiologic features with HIBI. Analogous to the  
19 methods used in our study, in patients with TBI, we can use the dynamic relationship between  
20 MAP and either intracranial pressure or brain tissue oxygen to assess autoregulation, and thus  
21 determine MAP<sub>OPT</sub><sup>25</sup>. Studies have consistently demonstrated that MAP<sub>OPT</sub> is often greater than  
22 80 or 90 mmHg in patients with TBI<sup>12,26</sup>. Furthermore, observational data indicate that patients  
23 who are maintained within 5 mmHg of their optimal MAP have decreased mortality and  
24 improved neurological outcomes<sup>12</sup>. However, the invasive methods used to determine MAP<sub>OPT</sub>  
25 may not be routinely practical in patients after cardiac arrest.

26 In an attempt to characterize cerebral autoregulation and patient specific MAP targets,  
27 Ameloot and colleagues performed a historical cohort study of 51 cardiac arrest patients who  
28 underwent continuous MAP and cerebral oximetry monitoring for the first 24 hours of their ICU  
29 stay<sup>6</sup>. They demonstrated that 35% of patients had disturbed autoregulation as defined where the  
30 slope of a linear regression equation (rSO<sub>2</sub>%/mmHg) of > 0.05%/mmHg. In patients with

1 preserved autoregulation,  $MAP_{OPT}$  was 85 mmHg, similar to the results seen in our study.  
2 Finally, the time under the individual  $MAP_{OPT}$  was associated with a small effect on survival  
3 (OR 0.97, 95%CI: 0.96 to 0.99,  $P=0.02$ ). In contrast to our study in which the ICM+ ® brain  
4 monitoring software is able to calculate COx in real-time, Ameloot and colleagues  
5 retrospectively calculated COx in order to determine the optimal MAP. The COx approach has  
6 also been used extensively and validated as a bedside measure of cerebral autoregulation in  
7 stroke<sup>14</sup>, sepsis<sup>27</sup> and subarachnoid hemorrhage<sup>28</sup>.

8 We demonstrated a lower proportion of time of dysfunctional autoregulation than  
9 reported by Ameloot and colleagues<sup>6</sup>. In their study, the authors defined autoregulation as  
10 present when the slope of the linear regression prediction was  $<0.05\%/mmHg$ , and absent when  
11 the slope was higher than this threshold. Under their definition, patients with up-sloping (figure  
12 2c) or down-sloping (figure 2d) relationships between COx and MAP would have been labeled  
13 as disturbed autoregulation. This may not be correct as patients do maintain the ability to  
14 autoregulate, but the range of observable MAP spans the autoregulatory thresholds.  
15 Furthermore, using linear regression may introduce model misspecification when the true  
16 relationship may in fact be non-linear. These concerns highlight the limitations of many studies  
17 examining autoregulation, including our own: the definition of adequate or dysfunctional  
18 cerebral autoregulation. These studies all have the underlying assumption of a fixed  
19 autoregulatory curve. Autoregulation is more likely dynamic with regional and temporal  
20 heterogeneity<sup>3</sup>. In addition, studies use varying definitions of what constitutes dysfunctional  
21 autoregulation: near zero slope of the relationship between COx and MAP<sup>6</sup>, specific COx  
22 thresholds<sup>8,14</sup>, or the inability to calculate  $MAP_{OPT}$ <sup>29</sup>. We chose a COx threshold of 0.3 or above  
23 to indicate dysfunctional autoregulation. This approach allows for a time-dependent change in  
24 the autoregulatory curve, which may not be seen with the other methods listed. This also  
25 allowed us to examine non-linear relationships between COx and MAP, and thus addressing the  
26 constraints placed by linear regression.

27 Much like our study, Pham and colleagues prospectively assessed COx (termed tissue  
28 oxygenation index –  $TO_x$ ) in 23 patients following cardiac arrest<sup>9</sup>. They defined dysfunctional  
29 autoregulation as a COx greater than 0, a lower threshold than used in our study. We chose 0.3  
30 as this represents the threshold used in previously published studies<sup>8,30,31</sup>. However, it is likely  
31 that there is no specific threshold for dysfunctional autoregulation, rather it is a continuum. This

1 is suggested in patients with TBI where an autoregulatory threshold for favorable outcome (0.05)  
2 was lower than for survival (0.25)<sup>32</sup>. Further work is needed to delineate the definition of  
3 dysfunctional autoregulation as it relates to clinical outcomes.

4 In patients with traumatic brain injury, rapid rewarming above 37°C results in  
5 dysfunction autoregulation<sup>33</sup>. Likewise, there is evidence that hyperthermia may be detrimental  
6 following cardiac arrest<sup>34,35</sup>. Although the specific target temperature remains unclear,  
7 temperature control, with strict avoidance of hyperthermia, remains an important management  
8 priority following cardiac arrest<sup>2,36</sup>. Our results suggest that hyperthermia may result in  
9 dysfunctional autoregulation in this population. However this interpretation may be skewed by  
10 the few patients with marked hyperthermia. The important relationship between temperature and  
11 cerebral autoregulation deserves further investigation.

12 Because this was a proof-of-concept study, this study was not designed to rigorously  
13 examine for clinically important outcomes. Thus, any inference regarding the relationship  
14 between COx and either MAP or temperature should be interpreted with caution. Finally, we do  
15 not have granular data on arterial carbon dioxide, an important potential modifier of cerebral  
16 autoregulation.

17

## 18 Conclusion

19 In our single-centre proof-of-concept study, we demonstrated the ability to assess  
20 cerebral autoregulation and determine a MAP<sub>OPT</sub> using cerebral oximetry in patients after cardiac  
21 arrest. This study justifies further observational work to examine the relationship between COx  
22 and time-within MAP<sub>OPT</sub> ranges and neurologic outcomes.

## 23 Acknowledgements

24 The authors would like to thank Medtronic PLC who provided the INVOS® monitor and  
25 sensors free of charge. Medtronic had no involvement in study concept, design, conduct,  
26 analysis or interpretation. We would also like to thank Jennifer K. Lee, MD (Assistant  
27 Professor, Johns Hopkins University School of Medicine) for all her of advice and help with the  
28 initial setup of the INVOS® and ICM+® brain monitoring software.

1 **Conflicts of interest**

2 ICM+ software is licensed by Cambridge Enterprise Ltd, UK. PS and MC have financial  
3 interest in a part of licensing fee. None of the other authors have any other conflicts of interest to  
4 declare.

5  
6 **Ethical standards**

7 All human studies have been approved by the appropriate ethics committee and have  
8 therefore been performed in accordance with the ethical standards laid down in the 1964  
9 Declaration of Helsinki and its later amendments.

10

11 **Authors' Contribution**

12 **Dr. Donald Griesdale and Dr. Mypinder Sekhon** were the co-principal investigators and  
13 responsible for the concept and design of the study. They collected all of the data for the study.  
14 They had access to all of the data and takes full responsibility for the integrity of the data and the  
15 accuracy of the data analysis. They were also involved in interpretation of the data and drafting  
16 of the manuscript. They have no conflicts of interest and approves of the final submitted version  
17 of the manuscript.

18 **Dr. Penny Brasher** performed part of the primary statistical analysis for the study. She was  
19 involved in data interpretation and drafting the manuscript. She has no conflicts of interest and  
20 approves of the final version of the manuscript.

21 **Dr. Peter Smielewski** was involved in the study design and interpretation of the study. He also  
22 wrote the configuration files to ensure that our bedside monitors would communicate with  
23 ICM+®. He help prepare and critically review the manuscript. He has no conflicts of interest  
24 and approves of the final version of the manuscript.

25 **Dr. Tahara D Bhate** collected data and was involved in data interpretation and manuscript  
26 preparation. She has no conflicts of interest and approve of the final version of the manuscript.

27 **Ms. Denise Foster** was involved with the study design. She collected data and was involved in  
28 interpreting and preparing the manuscript. She has no conflicts of interest and approve of the  
29 final version of the manuscript.

1 **Drs. David Menon, Arun Gupta, Marek Czosnyka, William Henderson, Kenneth Gin and**  
2 **Graham Wong** were all involved with the study design. They also contributed in writing the  
3 final version of the manuscript. They all approve of the final version of the manuscript.  
4

## 5 References

- 6 1. Laver S, Farrow C, Turner D, Nolan J. Mode of death after admission to an intensive care  
7 unit following cardiac arrest. *Intensive Care Med* 2004;30:2126–8.
- 8 2. Nielsen N, Wetterslev J, Cronberg T, Erlinge D, Gasche Y, Hassager C, et al. Targeted  
9 temperature management at 33°C versus 36°C after cardiac arrest. *N Engl J Med*  
10 2013;369:2197–206.
- 11 3. Nolan JP, Neumar RW, Adrie C, Aibiki M, Berg RA, Böttiger BW, et al. Post-cardiac  
12 arrest syndrome: epidemiology, pathophysiology, treatment, and prognostication. A  
13 Scientific Statement from the International Liaison Committee on Resuscitation; the  
14 American Heart Association Emergency Cardiovascular Care Committee; the Coun.  
15 Resuscitation 2008;79:350–79.
- 16 4. Sundgreen C, Larsen FS, Herzog TM, Knudsen GM, Boesgaard S, Aldershvile J.  
17 Autoregulation of Cerebral Blood Flow in Patients Resuscitated From Cardiac Arrest.  
18 *Stroke* 2001;32:128–32.
- 19 5. Peberdy MA, Callaway CW, Neumar RW, Geocadin RG, Zimmerman JL, Donnino M, et  
20 al. Part 9: Post-Cardiac Arrest Care: 2010 American Heart Association Guidelines for  
21 Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. *Circulation*  
22 2010;122:S768–86.
- 23 6. Ameloot K, Genbrugge C, Meex I, Jans F, Boer W, Vander Laenen M, et al. An  
24 observational near-infrared spectroscopy study on cerebral autoregulation in post-cardiac  
25 arrest patients: Time to drop “one-size-fits-all” hemodynamic targets? *Resuscitation*  
26 2015;90:121–6.
- 27 7. Lee JK, Brady KM, Chung S-E, Jennings JM, Whitaker EE, Aganga D, et al. A pilot study  
28 of cerebrovascular reactivity autoregulation after pediatric cardiac arrest. *Resuscitation*  
29 2014;
- 30 8. Brady KM, Lee JK, Kibler KK, Smielewski P, Czosnyka M, Easley RB, et al. Continuous  
31 time-domain analysis of cerebrovascular autoregulation using near-infrared spectroscopy.  
32 *Stroke* 2007;38:2818–25.
- 33 9. Pham P, Bindra J, Chuan A, Jaeger M, Aneman A. Are changes in cerebrovascular  
34 autoregulation following cardiac arrest associated with neurological outcome? Results of a  
35 pilot study. *Resuscitation* 2015;96:192–8.
- 36 10. Schmidt EA, Czosnyka M, Gooskens I, Piechnik SK, Matta BF, Whitfield PC, et al.  
37 Preliminary experience of the estimation of cerebral perfusion pressure using transcranial  
38 Doppler ultrasonography. *J Neurol Neurosurg Psychiatry* 2001;70:198–204.
- 39 11. Czosnyka M, Whitehouse H, Smielewski P, Kirkpatrick P, Guazzo EP, Pickard JD.  
40 Computer supported multimodal bed-side monitoring for neuro intensive care. *Int J Clin*

- 1 Monit Comput 1994;11:223–32.
- 2 12. Aries MJH, Czosnyka M, Budohoski KP, Steiner LA, Lavinio A, Koliass AG, et al.  
3 Continuous determination of optimal cerebral perfusion pressure in traumatic brain injury.  
4 Crit Care Med 2012;40:2456–63.
- 5 13. Smielewski P, M A, Lavinio A, Budohoski KP, Pickard J, Menon D, et al. Use of ICM+  
6 Software for tracking “Optimal” CPP Values in Real Time. Eur J Anaesthesiol  
7 2012;29:A34.
- 8 14. Brady K, Joshi B, Zweifel C, Smielewski P, Czosnyka M, Easley RB, et al. Real-time  
9 continuous monitoring of cerebral blood flow autoregulation using near-infrared  
10 spectroscopy in patients undergoing cardiopulmonary bypass. Stroke 2010;41:1951–6.
- 11 15. Kilgannon JH, Roberts BW, Jones AE, Mittal N, Cohen E, Mitchell J, et al. Arterial blood  
12 pressure and neurologic outcome after resuscitation from cardiac arrest\*. Crit Care Med  
13 2014;42:2083–91.
- 14 16. Bray JE, Bernard S, Cantwell K, Stephenson M, Smith K. The association between  
15 systolic blood pressure on arrival at hospital and outcome in adults surviving from out-of-  
16 hospital cardiac arrests of presumed cardiac aetiology. Resuscitation 2014;85:509–15.
- 17 17. Kilgannon JH, Roberts BW, Reihl LR, Chansky ME, Jones AE, Dellinger RP, et al. Early  
18 arterial hypotension is common in the post-cardiac arrest syndrome and associated with  
19 increased in-hospital mortality. Resuscitation 2008;79:410–6.
- 20 18. Kaji AH, Hanif AM, Thomas JL, Niemann JT. Out-of-hospital cardiac arrest: early in-  
21 hospital hypotension versus out-of-hospital factors in predicting in-hospital mortality  
22 among those surviving to hospital admission. Resuscitation 2011;82:1314–7.
- 23 19. Trzeciak S, Jones AE, Kilgannon JH, Milcarek B, Hunter K, Shapiro NI, et al.  
24 Significance of arterial hypotension after resuscitation from cardiac arrest\*. Crit Care Med  
25 2009;37:2895–903.
- 26 20. Young MN, Hollenbeck RD, Pollock JS, Giuseffi JL, Wang L, Harrell FE, et al. Higher  
27 achieved mean arterial pressure during therapeutic hypothermia is not associated with  
28 neurologically intact survival following cardiac arrest. Resuscitation 2015;88:158–64.
- 29 21. Bhate TD, McDonald B, Sekhon MS, Griesdale DEG. Association between blood  
30 pressure and outcomes in patients after cardiac arrest: A systematic review. Resuscitation  
31 2015;97:1–6.
- 32 22. Jones AE, Shapiro NI, Kilgannon JH, Trzeciak S. Goal-directed hemodynamic  
33 optimization in the post-cardiac arrest syndrome: a systematic review. Resuscitation  
34 2008;77:26–9.
- 35 23. Nishizawa H, Kudoh I. Cerebral autoregulation is impaired in patients resuscitated after  
36 cardiac arrest. Acta Anaesthesiol Scand 1996;40:1149–53.
- 37 24. Gaieski DF, Beylin ME, Abella BS, Grossestreuer A V, Perman SM. What is the optimal  
38 post-arrest hemodynamic strategy? Towards personalized resuscitation strategies. Int Care  
39 Med 2014;3197.
- 40 25. Bouzat P, Sala N, Payen J-F, Oddo M. Beyond intracranial pressure: optimization of

- 1 cerebral blood flow, oxygen, and substrate delivery after traumatic brain injury. *Ann*  
2 *Intensive Care* 2013;3:23.
- 3 26. Griesdale DEG, Ortenwall V, Norena M, Wong H, Sekhon MS, Kolmodin L, et al.  
4 Adherence to guidelines for management of cerebral perfusion pressure and outcome in  
5 patients who have severe traumatic brain injury. *J Crit Care* 2014;
- 6 27. Steiner LA, Pfister D, Strebel SP, Radolovich D, Smielewski P, Czosnyka M. Near-  
7 infrared spectroscopy can monitor dynamic cerebral autoregulation in adults. *Neurocrit*  
8 *Care* 2009;10:122–8.
- 9 28. Budohoski KP, Czosnyka M, Smielewski P, Varsos G V, Kasproicz M, Brady KM, et al.  
10 Cerebral autoregulation after subarachnoid hemorrhage: comparison of three methods. *J*  
11 *Cereb Blood Flow Metab* 2013;33:449–56.
- 12 29. Weersink CSA, Aries MJH, Dias C, Liu MX, Koliass AG, Donnelly J, et al. Clinical and  
13 Physiological Events That Contribute to the Success Rate of Finding “Optimal” Cerebral  
14 Perfusion Pressure in Severe Brain Trauma Patients. *Crit Care Med* 2015;43:1952–63.
- 15 30. Budohoski KP, Czosnyka M, de Riva N, Smielewski P, Pickard JD, Menon DK, et al. The  
16 relationship between cerebral blood flow autoregulation and cerebrovascular pressure  
17 reactivity after traumatic brain injury. *Neurosurgery* 2012;71:652–60; discussion 660–1.
- 18 31. Brady K, Joshi B, Zweifel C, Smielewski P, Czosnyka M, Easley RB, et al. Real-time  
19 continuous monitoring of cerebral blood flow autoregulation using near-infrared  
20 spectroscopy in patients undergoing cardiopulmonary bypass. *Stroke* 2010;41:1951–6.
- 21 32. Sorrentino E, Diedler J, Kasproicz M, Budohoski KP, Haubrich C, Smielewski P, et al.  
22 Critical thresholds for cerebrovascular reactivity after traumatic brain injury. *Neurocrit*  
23 *Care* 2012;16:258–66.
- 24 33. Lavinio A, Timofeev I, Nortje J, Outtrim J, Smielewski P, Gupta A, et al. Cerebrovascular  
25 reactivity during hypothermia and rewarming. *Br J Anaesth* 2007;99:237–44.
- 26 34. Hypothermia after Cardiac Arrest Study Group. Mild therapeutic hypothermia to improve  
27 the neurologic outcome after cardiac arrest. *N Engl J Med* 2002;346:549–56.
- 28 35. Bernard SA, Gray TW, Buist MD, Jones BM, Silvester W, Gutteridge G, et al. Treatment  
29 of comatose survivors of out-of-hospital cardiac arrest with induced hypothermia. *N Engl*  
30 *J Med* 2002;346:557–63.
- 31 36. Callaway CW, Donnino MW, Fink EL, Geocadin RG, Golan E, Kern KB, et al. Part 8:  
32 Post-Cardiac Arrest Care. *Circulation* 2015;132:S465–82.

33

34

35

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

## Figure Legends

**Figure 1:** Clinical recording from ICM+ ® brain monitoring software of a patient in order to generate the optimal mean arterial pressure (MAP<sub>OPT</sub>) over an 8-hour period. The first three planes are the MAP, regional saturation of oxygen (rSO<sub>2</sub>), and COx. The COx is a moving Pearson correlation coefficient between 30 consecutive, 10-sec averaged values of MAP and the corresponding rSO<sub>2</sub> signals. The bottom panel is the COx plotted against the intervals of MAP in 5 mmHg. A U-shaped curve is plotted with the nadir of the curve being MAP<sub>OPT</sub>.

**Figure 2.** Scatter plot between COx and the corresponding MAP over a 6-hour period for four individual patients. The light grey dots are corresponding COx and MAP measurements. The black boxes and lines represent median and IQR for COx values within 5mmHg width bins of MAP. The dashed line is at a COx of 0.3 which is the threshold for autoregulation. Values above that line indicated lack of autoregulation. The demonstrated relationships include: U-shaped (2A), flat (2B), upsloping (2C) and down-sloping (2D).

**Figure 3:** Density plot of the difference between the actual MAP and the MAP<sub>OPT</sub> (as determined using COx) for each hour over the entire study period. Each bin is a width of 5 mmHg.

**Figure 4.** Scatter plot between COx and temperature. The light grey solid lines are a locally weighted scatterplot smooth for each patient. The solid black line is a predicted curve generated using a restricted cubic splines model. Using multivariable polynomial fractional regression, there was a non-linear relationship between COx and temperature with increasing COx with hyperthermia (P=0.008).



## 1 Abbreviations

AHA	American Heart Association
CCU	coronary care unit
CO <sub>x</sub>	Correlational coefficient between MAP and rSO <sub>2</sub>
CPP	cerebral perfusion pressure
FV <sub>d</sub> / FV <sub>m</sub>	Flow Velocity diastolic / mean
HIBI	hypoxemic ischemic brain injury
ICP	intracranial pressure
ICU	intensive care unit
IQR	Interquartile range
MAP	mean arterial pressure
MAP <sub>OPT</sub>	optimal mean arterial pressure
ONSD	optic nerve sheath diameter
ROSC	return of spontaneous circulation
rSO <sub>2</sub>	regional saturation of oxygen
SD	standard deviation
TBI	traumatic brain injury
TCD	transcranial Doppler

2

Table 1. Baseline characteristics of cohort

	<b>Cohort (n=20)</b>	<b>Survivors (n=9)</b>	<b>Non-survivors (n=11)</b>
<b>Age in years, median (IQR)</b>	59 (54 – 67)	55 (48 – 66)	65 (57 – 67)
<b>Female sex, n (%)</b>	6 (30)	4 (44)	2 (18)
<b>Etiology of arrest, n(%)</b>			
<b>Myocardial ischemia / infarction</b>	12 (60)	8 (89)	4 (36)
<b>Hypoxemia</b>	4 (20)	0	4 (36)
<b>Other</b>	4 (20)	1 (11)	3 (28)
<b>Out of hospital arrest, n(%)</b>	17 (85)	9 (100)	8 (73)
<b>Witnessed arrest, n(%)</b>	19 (95)	9 (100)	10 (91)
<b>Shockable rhythm, n(%)</b>	6 (30)	4 (44)	2 (18)
<b>Epinephrine dose in miligrams, median (IQR)</b>	2 (1 – 6)	5 (1 – 10)	1.5 (1 – 3)
<b>Minutes prior to CPR, median (IQR)</b>	0 (0 – 0)	0 (0 – 0)	0 (0 – 10)
<b>Minutes prior to ROSC, median (IQR)</b>	15 (5 – 33)	5 (4 – 16)	24 (11 – 33)
<b>Percutaneous intervention, n(%)</b>	10 (50)	8 (89)	2 (18)

IQR = interquartile range; CPR = cardiopulmonary resuscitation; ROSC = return of spontaneous circulation;

Table 2: Management characteristics of cohort

	<b>Cohort (n=20)</b>	<b>Survivors (n=9)</b>	<b>Non-survivors (n=11)</b>
<b>Temperature in °C, mean (SD)</b>	36.4 (1.8)	36.5 (1.6)	36.2 (1.9)
<b>PaCO<sub>2</sub> in mmHg, mean (SD)</b>	37 (9)	38 (9)	36 (10)
<b>Hemoglobin in g/L, mean (SD)</b>	121 (20)	115 (24)	126 (16)
<b>MAP in mmHg, mean (SD)</b>	76 (10)	79 (8)	74 (11)
<b>MAP<sub>OPT</sub> in mmHg, mean (SD)</b>	76 (7)	77 (7)	75 (8)
<b>rSO<sub>2</sub> %, mean (SD)</b>	59 (11)	57 (5)	65 (14)
<b>COx, mean (SD)</b>	0.066 (0.11)	0.034 (0.047)	0.099 (0.14)
<b>Percent of time with COx ≥ 0.3, median (IQR)</b>	13 (6 – 19)	10 (6 – 13)	18 (7 - 41)
<b>Norepinephrine use, n(%)</b>	19 (95)	8 (89)	11 (100)
<b>Norepinephrine dose in mcg/min, mean (SD)</b>	12 (13)	11 (13)	12 (13)
<b>Dobutamine use, n(%)</b>	3 (15)	2 (22)	1 (9)
<b>Dobutamine dose in mcg/kg/min, mean (SD)</b>	5.3 (1)	6 (1)	4.5 (4)
<b>Propofol dose in mcg/kg/min, mean (SD)</b>	40 (15)	44 (19)	36 (12)

MAP = mean arterial pressure; rSO<sub>2</sub> = regional saturation of oxygen; PaCO<sub>2</sub> = arterial carbon dioxide tension;

IQR = interquartile range; CPR = cardiopulmonary resuscitation; ROSC = return of spontaneous circulation;







